Alterations of the central noradrenergic system in MPTP-induced monkey parkinsonism - PubMed (original) (raw)
Affiliations
- PMID: 2849789
Alterations of the central noradrenergic system in MPTP-induced monkey parkinsonism
R Miyoshi et al. Res Commun Chem Pathol Pharmacol. 1988 Oct.
Abstract
Alterations of the coeruleo-cortical adrenergic system in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced monkey parkinsonism were examined through neuropathological observation and radioreceptor assay. Neuronal degeneration was found not only in the substantia nigra but also in the locus coeruleus of all the MPTP-treated monkeys. From radioreceptor assay, decreases of alpha 1 and alpha 2 receptors in the parietal and temporal cortices were observed in parkinsonian monkeys. In addition, beta receptors increased in the temporal cortex. These changes in monkey parkinsonism are very similar to those in human Parkinson's disease.
Similar articles
- Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys.
Forno LS, Langston JW, DeLanney LE, Irwin I, Ricaurte GA. Forno LS, et al. Ann Neurol. 1986 Oct;20(4):449-55. doi: 10.1002/ana.410200403. Ann Neurol. 1986. PMID: 3024555 - The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Burns RS, LeWitt PA, Ebert MH, Pakkenberg H, Kopin IJ. Burns RS, et al. N Engl J Med. 1985 May 30;312(22):1418-21. doi: 10.1056/NEJM198505303122203. N Engl J Med. 1985. PMID: 2581135 - [Significance of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine for the etiology and therapy of idiopathic Parkinson disease].
Lange KW. Lange KW. Fortschr Neurol Psychiatr. 1989 Apr;57(4):142-8. doi: 10.1055/s-2007-1000755. Fortschr Neurol Psychiatr. 1989. PMID: 2656447 Review. German. - The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
Jenner P, Marsden CD. Jenner P, et al. J Neural Transm Suppl. 1986;20:11-39. J Neural Transm Suppl. 1986. PMID: 3091760 Review.
Cited by
- Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.
Duty S, Jenner P. Duty S, et al. Br J Pharmacol. 2011 Oct;164(4):1357-91. doi: 10.1111/j.1476-5381.2011.01426.x. Br J Pharmacol. 2011. PMID: 21486284 Free PMC article. Review. - Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys.
Masilamoni GJ, Bogenpohl JW, Alagille D, Delevich K, Tamagnan G, Votaw JR, Wichmann T, Smith Y. Masilamoni GJ, et al. Brain. 2011 Jul;134(Pt 7):2057-73. doi: 10.1093/brain/awr137. Brain. 2011. PMID: 21705423 Free PMC article. - The catecholaminergic neurotransmitter system in methylmercury-induced neurotoxicity.
Farina M, Aschner M, da Rocha JBT. Farina M, et al. Adv Neurotoxicol. 2017;1:47-81. doi: 10.1016/bs.ant.2017.07.002. Epub 2017 Sep 1. Adv Neurotoxicol. 2017. PMID: 32346666 Free PMC article. No abstract available. - Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice.
Rommelfanger KS, Edwards GL, Freeman KG, Liles LC, Miller GW, Weinshenker D. Rommelfanger KS, et al. Proc Natl Acad Sci U S A. 2007 Aug 21;104(34):13804-9. doi: 10.1073/pnas.0702753104. Epub 2007 Aug 16. Proc Natl Acad Sci U S A. 2007. PMID: 17702867 Free PMC article. - Noradrenaline and Parkinson's disease.
Delaville C, Deurwaerdère PD, Benazzouz A. Delaville C, et al. Front Syst Neurosci. 2011 May 18;5:31. doi: 10.3389/fnsys.2011.00031. eCollection 2011. Front Syst Neurosci. 2011. PMID: 21647359 Free PMC article.